PH26554A - Inhibitory agent of hepatic fibrosis - Google Patents

Inhibitory agent of hepatic fibrosis Download PDF

Info

Publication number: PH26554A
Authority: PH; Philippines
Prior art keywords: fibrosis; pantethine; hepatic; hepatic fibrosis; inhibitory agent
Prior art date: 1988-01-06

Application number

PH38005A

Other languages

English (en)

Inventor

Munehiro Tomikawa

Junichiro Wakasugi

Original Assignee

Daiichi Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-01-06

Filing date

1989-01-05

Publication date

1992-08-19

1989-01-05 Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co

1992-08-19 Publication of PH26554A publication Critical patent/PH26554A/en

Links

206010019668 Hepatic fibrosis Diseases 0.000 title claims description 9
230000002401 inhibitory effect Effects 0.000 title claims description 9
DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 11
DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 11
229960000903 pantethine Drugs 0.000 claims description 11
235000008975 pantethine Nutrition 0.000 claims description 11
239000011581 pantethine Substances 0.000 claims description 11
206010016654 Fibrosis Diseases 0.000 claims description 9
230000004761 fibrosis Effects 0.000 claims description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 6
230000002440 hepatic effect Effects 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
102000004079 Prolyl Hydroxylases Human genes 0.000 description 5
108010043005 Prolyl Hydroxylases Proteins 0.000 description 5
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
229940107161 cholesterol Drugs 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000037213 diet Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000000203 mixture Substances 0.000 description 3
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000243 solution Substances 0.000 description 2
101150039167 Bex3 gene Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
208000004930 Fatty Liver Diseases 0.000 description 1
206010016334 Feeling hot Diseases 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
235000008694 Humulus lupulus Nutrition 0.000 description 1
244000025221 Humulus lupulus Species 0.000 description 1
241000521257 Hydrops Species 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
201000010549 croup Diseases 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
208000010706 fatty liver disease Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
231100000240 steatosis hepatitis Toxicity 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PH38005A 1988-01-06 1989-01-05 Inhibitory agent of hepatic fibrosis PH26554A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP106788		1988-01-06

Publications (1)

Publication Number	Publication Date
PH26554A true PH26554A (en)	1992-08-19

Family

ID=11491185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38005A PH26554A (en)	1988-01-06	1989-01-05	Inhibitory agent of hepatic fibrosis

Country Status (8)

Country	Link
US (1)	US4937266A (ko)
EP (1)	EP0323855B1 (ko)
KR (1)	KR970005324B1 (ko)
AU (1)	AU614569B2 (ko)
CA (1)	CA1318254C (ko)
DE (1)	DE68914468T2 (ko)
ES (1)	ES2054881T3 (ko)
PH (1)	PH26554A (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH02232670A (ja) *	1989-03-06	1990-09-14	Minolta Camera Co Ltd	複写機
US6046219A (en) *	1995-01-20	2000-04-04	Cornell Research Foundation, Inc.	Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5789426A (en) *	1995-01-20	1998-08-04	Cornell Research Foundation, Inc.	Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US5965621A (en) *	1995-08-17	1999-10-12	Allergan	Methods and compositions for reducing or maintaining body weight in a mammal
WO2002098405A1 (fr) *	2001-06-05	2002-12-12	Ajinomoto Co., Inc.	Inhibiteurs de fibrose du foie
DK2712617T3 (en)	2004-03-12	2017-02-13	Intercept Pharmaceuticals Inc	Treatment of fibrosis with Fxr ligands.
DK2953948T3 (en)	2013-02-07	2017-12-18	Scifluor Life Sciences Inc	FLUORINATED INTEGRIN ANTAGONISTS
RU2017132433A (ru)	2015-02-19	2019-03-19	Сайфлуор Лайф Сайенсиз, Инк.	Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение
CN108040467A (zh)	2015-04-30	2018-05-15	赛弗卢尔生命科学公司	四氢萘啶基丙酸衍生物及其用途
US10118929B2 (en)	2016-04-27	2018-11-06	Scifluor Life Sciences, Inc.	Nonanoic and decanoic acid derivatives and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6019891B2 (ja) *	1978-12-01	1985-05-18	第一製薬株式会社	薬物性脂肪肝用剤
JPS55102567A (en) *	1979-01-30	1980-08-05	Dai Ichi Seiyaku Co Ltd	Nicotinoylpantethine derivative
JPS5835118A (ja) *	1981-08-28	1983-03-01	Dai Ichi Seiyaku Co Ltd	肝炎治療剤
GB2110536B (en) *	1981-12-04	1986-10-29	Sogo Pharm	Pharmaceutical compositions containing pantetheine-s-sulphonic acid

1988
- 1988-12-29 CA CA000587236A patent/CA1318254C/en not_active Expired - Fee Related
1989
- 1989-01-03 US US07/292,793 patent/US4937266A/en not_active Expired - Fee Related
- 1989-01-04 AU AU27723/89A patent/AU614569B2/en not_active Ceased
- 1989-01-05 ES ES89100180T patent/ES2054881T3/es not_active Expired - Lifetime
- 1989-01-05 KR KR1019890000030A patent/KR970005324B1/ko not_active IP Right Cessation
- 1989-01-05 PH PH38005A patent/PH26554A/en unknown
- 1989-01-05 DE DE68914468T patent/DE68914468T2/de not_active Expired - Fee Related
- 1989-01-05 EP EP89100180A patent/EP0323855B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE68914468D1 (de)	1994-05-19
EP0323855A3 (en)	1990-12-05
DE68914468T2 (de)	1994-07-28
CA1318254C (en)	1993-05-25
EP0323855A2 (en)	1989-07-12
AU2772389A (en)	1989-07-13
EP0323855B1 (en)	1994-04-13
US4937266A (en)	1990-06-26
AU614569B2 (en)	1991-09-05
ES2054881T3 (es)	1994-08-16
KR970005324B1 (ko)	1997-04-15
KR890011588A (ko)	1989-08-21

Publication	Publication Date	Title
Middeldorp et al.	2000	Effects on coagulation of levonorgestrel-and desogestrel-containing low dose oral contraceptives: a cross-over study
PH26554A (en)	1992-08-19	Inhibitory agent of hepatic fibrosis
Valentine et al.	1957	The relationship of leukocyte alkaline phosphatase to “stress,” to ACTH, and to adrenal 17-OH-corticosteroids
Edwards et al.	1993	Nitric oxide‐related vasodilator responses to parasympathetic stimulation of the submandibular gland in the cat.
Giambalvo	1992	Protein kinase C and dopamine transport—1. Effects of amphetamine in vivo
DE69530308T2 (de)	2003-10-16	Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
Lazarow et al.	1950	Protection against diabetes with nicotinamide
DE2923009A1 (de)	1980-01-03	Mittel zur prophylaxe und behandlung der fibrose
EP0759693A4 (en)	1999-06-09	METHOD FOR IDENTIFYING COMPOUNDS THAT CAN UNBIND BINDING INTERACTIONS BETWEEN HIV-1 AND VPR-RIP-1
KIMBERLY	1982	Pulse methylprednisolone in SLE
Lee et al.	1983	Age-related changes in esterase activity in rabbit eyes
ROBERTSON	1966	Serum cholinesterase deficiency I: disease and inheritance
Neubert et al.	1974	Induction of skeletal malformations in organ cultures of mammalian embryonic tissues
Zawalich et al.	1991	Influence of staurosporine on glucose-mediated and glucose-conditioned insulin secretion
Wanders et al.	1990	First prenatal diagnosis of acyl‐CoA oxidase deficiency
Kashfi et al.	1991	Malonyl-CoA inhibits proteolysis of carnitine palmitoyltransferase
Grodins et al.	1941	Observations on the toxicities and choleretic activities of certain bile salts
Verjee et al.	1977	Effect of glucocorticoids on liver and blood cholinesterases
Levin et al.	1956	Metabolism of phospholipides associated with cell division
Hartung et al.	1968	Cholinesterase inhibition in the acute toxicity of alkyl-substituted 2-aminoethanols
ATE71385T1 (de)	1992-01-15	Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten.
Kambam et al.	1988	Cimetidine does not affect plasma cholinesterase activity
JPH01279824A (ja)	1989-11-10	肝線維化抑制剤
Bryceson	2000	Visceral leishmaniasis in India
Haschek et al.	1981	Animal model of human disease. Diffuse interstitial pulmonary fibrosis. Pulmonary fibrosis in mice induced by treatment with butylated hydroxytoluene and oxygen.